Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Case report

Advanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case

Authors: Atene Itoh, Hiroshi Sadamori, Kazuhisa Yabushita, Kazuteru Monden, Masashi Tatsukawa, Masayoshi Hioki, Tsuyoshi Hyodo, Kunihiro Omonishi, Toru Ueki, Satoshi Ohno, Kohsaku Sakaguchi, Norihisa Takakura

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) patients with hepatic vein tumor thrombosis (HVTT) extending to the inferior vena cava (IVC) have an extremely poor prognosis. Here we report a case of HCC with HVTT and renal dysfunction after hepatic arterial infusion chemotherapy (HAIC) successfully treated by liver resection and active veno-venous bypass.

Case presentation

A 77-year-old man was diagnosed to have a large HCC with intrahepatic metastases and HVTT extending to the IVC. Due to the advanced stage, HAIC with cisplatin was performed 13 times in a period of 17 months. As a consequence of this treatment, the size of the main HCC markedly decreased, and the advanced part of the HVTT went down to the root of the right hepatic vein (RHV). However, because of renal dysfunction, HAIC with cisplatin was discontinued and right hepatectomy with patch graft venoplasty of the root of the RHV was performed. Because progression of renal dysfunction had to be avoided, veno-venous bypass was activated during IVC clamping to prevent renal venous congestion and hypotension. Histological examination showed foci of a moderately differentiated HCC with extensive fibrosis and necrosis in the main HCC. Histologically, the HVTT in the RHV showed massive necrosis and tightly adhered to the vascular wall of the RHV. The postoperative function of the remnant liver was good, and no further deterioration of renal function was detected. The patient did not show signs of recurrence 15 month after surgery.

Conclusion

In the present case, HAIC using cisplatin in combination with hepatic resection and patch graft venoplasty of the IVC provided a good long-term outcome with no HCC recurrence. Renal function was preserved by using active veno-venous bypass during IVC clamping to prevent renal venous congestion and hypotension.
Literature
1.
go back to reference Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis. Ann Surg. 1998;227:433–9.CrossRefPubMedPubMedCentral Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis. Ann Surg. 1998;227:433–9.CrossRefPubMedPubMedCentral
2.
go back to reference Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg. 2003;237:376–83.PubMedPubMedCentral Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg. 2003;237:376–83.PubMedPubMedCentral
3.
go back to reference Le Terut YP, Hardwigen J, Ananian P, Saisse J, Gregoire E, Richa H, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature: a European case–control series. J Gastrointest Surg. 2006;10:855–62.CrossRef Le Terut YP, Hardwigen J, Ananian P, Saisse J, Gregoire E, Richa H, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature: a European case–control series. J Gastrointest Surg. 2006;10:855–62.CrossRef
4.
go back to reference Pawlik TM, Poon RT, Abdalla EK, Ikai I, Narorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal tumour-cell invasion and migration: diversity and escape or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403–10.CrossRefPubMed Pawlik TM, Poon RT, Abdalla EK, Ikai I, Narorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal tumour-cell invasion and migration: diversity and escape or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403–10.CrossRefPubMed
5.
go back to reference Kokudo T, Hasegawa K, Yamamoto S, Shindoh J, Takemura N, Aoki T, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61:583–8.CrossRefPubMed Kokudo T, Hasegawa K, Yamamoto S, Shindoh J, Takemura N, Aoki T, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61:583–8.CrossRefPubMed
6.
go back to reference Wang Y, Yuan L, Ge RI, Sun Y, Wei G, et al. Surgical benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: Results of a retrospective cohort study. Ann Surg Oncol. 2013;20:914–22.CrossRefPubMed Wang Y, Yuan L, Ge RI, Sun Y, Wei G, et al. Surgical benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: Results of a retrospective cohort study. Ann Surg Oncol. 2013;20:914–22.CrossRefPubMed
7.
go back to reference Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, et al. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-αfor advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012;42:442–53.CrossRefPubMed Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, et al. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-αfor advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012;42:442–53.CrossRefPubMed
8.
go back to reference Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, et al. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular. Cancer Medicine. 2013;2:86–98.CrossRefPubMedPubMedCentral Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, et al. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular. Cancer Medicine. 2013;2:86–98.CrossRefPubMedPubMedCentral
9.
go back to reference Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation hepatic arterial infusion chemotherapy of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474–83.CrossRefPubMed Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation hepatic arterial infusion chemotherapy of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474–83.CrossRefPubMed
10.
go back to reference Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ. Pharmacokinetics of non-protein-bound species following administration of cis-dichlorodiammineplatinum (II). Cancer Treat Rep. 1979;63:1515–21.PubMed Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ. Pharmacokinetics of non-protein-bound species following administration of cis-dichlorodiammineplatinum (II). Cancer Treat Rep. 1979;63:1515–21.PubMed
11.
go back to reference Kawashiro T, Asakawa N. Pharmacokinetics of fine powder cisplatin (DDP-H) for intraarterial infusion chemotherapy. Antibiot Chemother. 2004;20:103–8. Japanese. Kawashiro T, Asakawa N. Pharmacokinetics of fine powder cisplatin (DDP-H) for intraarterial infusion chemotherapy. Antibiot Chemother. 2004;20:103–8. Japanese.
12.
go back to reference Collins JM. Pharmacokinetic rationale for intra-arterial therapy. In: Kimura K, editor. Cancer Chemotherapy, Challenges for the Future, vol. 4. Amsterdam: Excerpta Medica; 1989. p. 3–10. Collins JM. Pharmacokinetic rationale for intra-arterial therapy. In: Kimura K, editor. Cancer Chemotherapy, Challenges for the Future, vol. 4. Amsterdam: Excerpta Medica; 1989. p. 3–10.
13.
go back to reference Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902.CrossRefPubMedPubMedCentral Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902.CrossRefPubMedPubMedCentral
16.
go back to reference Nonami T, Nakao A, Harada A, Kaneko T, Kurokawa T, Takagi H. Hepatic resection for hepatocellular carcinoma with a tumor thrombus extending to inferior vena cava. Hepatogastroenterology. 1997;44:798–802.PubMed Nonami T, Nakao A, Harada A, Kaneko T, Kurokawa T, Takagi H. Hepatic resection for hepatocellular carcinoma with a tumor thrombus extending to inferior vena cava. Hepatogastroenterology. 1997;44:798–802.PubMed
17.
go back to reference Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol. 2012;24:186–94.CrossRefPubMed Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol. 2012;24:186–94.CrossRefPubMed
18.
go back to reference Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, et al. Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. World J Surg Oncol. 2013;11:259–68.CrossRefPubMedPubMedCentral Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, et al. Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. World J Surg Oncol. 2013;11:259–68.CrossRefPubMedPubMedCentral
19.
go back to reference Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.CrossRefPubMedPubMedCentral Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.CrossRefPubMedPubMedCentral
20.
go back to reference Wattad M, Darawsha W, Solomonica A, Hijazi M, Kaplan M, Makhoul BF, et al. Interaction between worsening renal function and persistent congestion in acute decompensated heart failure. Am J Cardiol. 2015;115:932–7.CrossRefPubMed Wattad M, Darawsha W, Solomonica A, Hijazi M, Kaplan M, Makhoul BF, et al. Interaction between worsening renal function and persistent congestion in acute decompensated heart failure. Am J Cardiol. 2015;115:932–7.CrossRefPubMed
21.
go back to reference Albalate M, Octavio JG, Llobregat R, Fuster JM. Acute renal failure due to aortocaval fistula. Nephrol Dial Transplant. 1998;13:1268–70.CrossRefPubMed Albalate M, Octavio JG, Llobregat R, Fuster JM. Acute renal failure due to aortocaval fistula. Nephrol Dial Transplant. 1998;13:1268–70.CrossRefPubMed
22.
go back to reference Weber T, Gewertz B, Stanley I, Lindenauer S, Fry W. Renal effects of acute infrarenal aortocaval fistula. J Surg Res. 1978;25:482–7.CrossRefPubMed Weber T, Gewertz B, Stanley I, Lindenauer S, Fry W. Renal effects of acute infrarenal aortocaval fistula. J Surg Res. 1978;25:482–7.CrossRefPubMed
23.
go back to reference Burke AM, Jamieson GG. Aortocaval fistula associated with ruptured aortic aneurysm. Br J Surg. 1983;70:431–3.CrossRefPubMed Burke AM, Jamieson GG. Aortocaval fistula associated with ruptured aortic aneurysm. Br J Surg. 1983;70:431–3.CrossRefPubMed
24.
go back to reference Fukuda S, Okuda K, Imamura M, Imamura I, Eriguchi N, Aoyagi S. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery. 2002;131:300–10.CrossRefPubMed Fukuda S, Okuda K, Imamura M, Imamura I, Eriguchi N, Aoyagi S. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery. 2002;131:300–10.CrossRefPubMed
25.
go back to reference Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007;110:2493–501.CrossRefPubMed Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007;110:2493–501.CrossRefPubMed
26.
go back to reference Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today. 2014;44:219–26.CrossRefPubMed Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today. 2014;44:219–26.CrossRefPubMed
Metadata
Title
Advanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case
Authors
Atene Itoh
Hiroshi Sadamori
Kazuhisa Yabushita
Kazuteru Monden
Masashi Tatsukawa
Masayoshi Hioki
Tsuyoshi Hyodo
Kunihiro Omonishi
Toru Ueki
Satoshi Ohno
Kohsaku Sakaguchi
Norihisa Takakura
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2749-4

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine